How semaglutide disrupts gastric electrical signals - the gastroparesis link

TL;DR

A small pilot study published in the Journal of Neurogastroenterology and Motility found that semaglutide weakened gastric muscle contractions and caused abnormal electrical activity in the stomach in 63% of patients. This is the first objective, measurable biomarker evidence explaining why GLP-1 medications like Ozempic and Wegovy cause nausea, early satiety, and in some patients, gastroparesis-like symptoms.

Most people know that GLP-1 medications slow down the stomach. That is literally part of how they work - delayed gastric emptying prolongs the feeling of fullness, reducing how much you eat. What has been less clear is the precise mechanism at the cellular level, and why some people on semaglutide experience persistent nausea, severe bloating, or in rare cases, signs of gastroparesis. A new pilot study gives us the closest look yet at what is actually happening inside the stomach.

The technology: mapping your stomach's electrical system

Your stomach does not just squeeze food mechanically. It runs on an electrical system - slow waves of electrical activity generated by specialised pacemaker cells in the gastric wall, called interstitial cells of Cajal. These waves coordinate muscle contractions to move food through the digestive tract at a controlled rate. When those electrical signals become irregular or weaker, the stomach does not empty properly.

Body surface gastric mapping (BSGM) is a non-invasive technology that measures gastric electrical activity from sensors placed on the skin - similar to how an ECG captures heart electrical signals. It can detect abnormalities in gastric rhythm and contraction amplitude without requiring invasive procedures.

Researchers in Australia used BSGM to measure gastric electrical function in patients prescribed semaglutide, before and after starting the medication. The study, published in the Journal of Neurogastroenterology and Motility in April 2026, was led by Ryan Abraham and colleagues at Campbelltown Hospital.

Who was in the study and what they found

The study enrolled 9 patients; 8 completed the full protocol (6 female, median age 55 years, median BMI 45 kg/m²). All were starting semaglutide via standard titration to a 1 mg weekly maintenance dose, and none had pre-existing gastrointestinal symptoms at baseline.

Key findings after starting semaglutide:

• 87.5% of patients showed decreased gastric electrical amplitude - weaker stomach muscle contractions
• 63% developed spectral abnormalities - irregular electrical activity patterns in the stomach
• 25% showed very low or undetectable gastric activity rhythm index scores, indicating potential dysrhythmia
• The fullness and early satiation subscale score increased significantly (p = 0.005)
• A trend toward increased gastroparesis symptoms was observed, though it did not reach statistical significance in this small sample

The muscle contraction reduction was statistically significant even after adjusting for BMI changes (p = 0.04). In plain terms: the stomach muscle was genuinely squeezing less forcefully after starting semaglutide, and nearly two-thirds of patients had measurable disruptions to their gastric electrical rhythm.

What this explains about GLP-1 GI side effects

GI side effects - nausea, bloating, vomiting, early satiety - are the most common reason people reduce their GLP-1 dose or stop treatment entirely. Rates of 20-44% nausea have been reported in clinical trials of semaglutide and tirzepatide at therapeutic doses. Until now, the explanation has been largely pharmacological: GLP-1 receptors in the gut slow gastric emptying. This study provides the first direct measurement of the electrical mechanism behind that effect.

The dysrhythmia findings are particularly relevant for people who experience severe or persistent GI symptoms on GLP-1 medications. Gastric electrical abnormalities are associated with conditions like gastroparesis - a clinical syndrome where the stomach empties too slowly, causing chronic nausea, vomiting, and bloating that can persist for months after stopping the medication.

The gastroparesis question

Case reports and FDA adverse event data have linked semaglutide and other GLP-1 medications to gastroparesis diagnoses. Researchers have debated whether GLP-1 medications cause gastroparesis or whether they unmask it in patients who were already at risk. This study does not settle that debate - the sample is far too small - but it does show measurable gastric electrical disruption in patients with no prior GI history, which strengthens the biological plausibility of a drug-induced mechanism.

The fact that 25% of participants in this study showed near-absent electrical activity rhythm suggests a subset of GLP-1 users may be more vulnerable to disrupted gastric motility. Whether that vulnerability is dose-dependent, genetic, or related to prior subclinical gut issues is not yet known. Early findings from this research suggest that gastric biomarker monitoring - using BSGM or similar tools - could eventually help identify higher-risk patients before severe symptoms develop.

What you can do if you experience persistent nausea on GLP-1 medications

GI side effects on Ozempic, Wegovy, or Mounjaro are real and common. Several practical approaches reduce their severity:

• Stick to the dose titration schedule - moving up doses too quickly dramatically worsens GI effects
• Eat smaller meals and avoid high-fat foods, which slow gastric emptying further
• Avoid eating within 3 hours of bedtime
• Stay well hydrated - dehydration worsens nausea
• Discuss dose reduction or temporary dose hold with your prescriber if symptoms are severe

Persistent nausea that does not improve after the first 4-8 weeks of a stable dose is worth discussing with your doctor. Gastroparesis-like symptoms that continue after stopping the medication require medical evaluation.

The nutrient absorption connection

Slower gastric emptying does not just affect how you feel - it affects how your body absorbs nutrients. Food moves through the digestive system more slowly when the stomach's electrical rhythm is disrupted. This can alter the absorption timing and efficiency of key micronutrients, including vitamin B12, iron, and magnesium - nutrients already at higher deficiency risk in GLP-1 users due to reduced food intake. People experiencing significant GI symptoms on semaglutide should pay particular attention to their nutrient status. GLP-1 Shield is designed to support the specific micronutrient gaps that GLP-1 medications create, including in users with GI sensitivity.

Frequently asked questions

Can semaglutide cause gastroparesis?

Case reports and FDA adverse event data have linked semaglutide to gastroparesis diagnoses. The new BSGM study shows measurable gastric electrical disruption in patients without prior GI history, strengthening the biological plausibility of drug-induced gastroparesis in a subset of users. Early findings suggest some patients may have a higher vulnerability, though researchers are still investigating which patients are most at risk.

Why does Ozempic cause nausea and bloating?

GLP-1 medications slow gastric emptying as part of their appetite-suppressing mechanism. This new pilot study shows semaglutide also disrupts the stomach's electrical rhythm in 63% of patients and weakens muscle contractions in 87.5%, both of which contribute directly to nausea, early satiety, and bloating. These effects are greatest in the first weeks of treatment and at higher doses.

Does GI disruption on GLP-1 medications affect nutrient absorption?

Yes. When food moves through the digestive system more slowly or irregularly, the absorption of micronutrients including vitamin B12, iron, and magnesium can be affected. This is an additional reason why GLP-1 users - especially those with persistent GI symptoms - should monitor their nutrient status and consider supplementation formulated for their specific needs.

When should I be concerned about my GI symptoms on semaglutide?

Mild nausea and bloating in the first 4-8 weeks at any new dose level is expected and usually resolves. Persistent severe symptoms at a stable dose, or symptoms that include vomiting, significant bloating, and inability to eat after the first few weeks, warrant a conversation with your prescriber. If GI symptoms continue after stopping the medication, seek medical evaluation for gastroparesis.